DWDillon Timothy Wademan

Dillon Timothy Wademan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dillon Timothy Wademan has a total of 152 co-authors. Here are the top co-authors by number of shared publications:

  • Graeme Hoddinott

    Sydney Infectious Diseases Institute, The University of Sydney , Sydney, New South Wales

    13 shared publications
  • James A. Seddon

    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    6 shared publications
  • Anneke C. Hesseling

    Affiliation Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    5 shared publications
  • Graeme Hoddinott

    Affiliations Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

    4 shared publications
  • Marieke Magrieta van der Zalm

    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    4 shared publications
  • Megan Palmer

    Affiliation Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    4 shared publications

Latest Publications

  • Open Access

    Response to “Long TB: Framing post-acute sequelae of tuberculosis as a distinct clinical entity”

    by Dillon T. Wademan, Marieke van der Zalm, Brian Allwood

    Was not provided for this article.

  • Open Access

    Using participatory methods to develop a narrative intervention to alleviate distress in children hospitalised with TB in South Africa: The DIMPle project

    by Caitlin D. October, Dzunisani P. Baloyi, Lario Viljoen, Rene Raad, Dillon T. Wademan, Megan Palmer, Juli Switala, Michaile G. Anthony, Karen Du Preez, Petra De Koker, et al.

    Children who are hospitalised for tuberculosis (TB) experience challenges that put them at risk of developing emotional, behavioural, and social difficulties. In this methodological paper, we showcase the development of a narrative intervention toolkit with key components of the resulting version 1.0 tool. The study design was participatory and pragmatic, with researchers working with the routine staff of TB hospital wards, children admitted and their caregivers, to iteratively understand and improve children’s experiences of hospitalisation. The project included three phases: (1) a situational analysis to map children and healthcare providers’ perspectives on priorities and potential intervention components, (2) co-development of a beta-version of the intervention, and (3) piloting and incremental refinement toward a version 1.0 of the intervention. The intervention toolkit combined a series of activities alongside the story of ‘Courageous Curly’ to facilitate children’s engagement with their own experiences of hospitalisation, including psychosocial and treatment challenges, captured, and described throughout data collection. We found that dividing the story into short chapters facilitated children’s engagement with the section of story that is being told on a specific day. Each chapter of the story follows/mimics a different stage children can expect during their treatment journey while hospitalised for TB care. Implementation and evaluation of such interventions can mitigate the psychosocial impact of TB in children and inform policies to improve their overall TB care.

  • Open Access

    Children, caregivers and health workers’ perceptions and experiences of the XTEMP-R tool to improve tuberculosis treatment

    by Dillon T. Wademan, Willdon J. Filander, Mfundo Mlomzale, Ntokozo Sibisi, Cyril Thwala, Phumlani Memela, Nosivuyile Vanqa, Megan Palmer, Tina Sachs, Munira Khan, et al.

    Treating drug-resistant tuberculosis (DR-TB) in children remains a significant challenge for patients, caregivers, and health systems, despite advances in child-friendly drug formulations. While new formulations offer benefits, their widespread availability is limited, and many exhibit poor palatability. A key strategy to improve administration and mask the taste of paediatric TB medications involves creating extemporaneous suspensions. However, this often requires pharmaceutical services not readily available in high-burden settings. To address this, the Global Alliance for TB Drug Development (TB Alliance) developed XTEMP-R, an inexpensive prototype tool designed to facilitate home-based preparation of liquid TB medication suspensions. This study explored the experiences and perceptions of children, their caregivers, and health workers regarding the XTEMP-R tool for preparing extemporaneous DR-TB treatment suspensions. We collected qualitative data from two sites in South Africa. The first component involved interviews with 17 caregivers and 12 health workers, followed by focus group discussions, with participants directly interacting with the XTEMP-R tool. The second component comprised 31 interviews with 11 caregivers of 13 children who used the XTEMP-R tool for home administration. Case descriptions were iteratively refined and analyzed using deductive thematic analysis. Findings indicate that children, caregivers, and health workers found the XTEMP-R tool easy to use, clean, and store, appreciating its appealing color and durability. Home users reported that the tool simplified treatment preparation and administration, reducing time and relational burdens associated with DR-TB treatment. While XTEMP-R effectively addressed usability challenges related to drug preparation, fundamental obstacles concerning medication palatability, nausea, and side effects remain significant barriers. Importantly, the tool appeared to foster increased treatment responsibility among some children, suggesting a potential pathway to improve therapeutic engagement and agency. This research underscores the XTEMP-R tool’s potential to ease paediatric DR-TB treatment and highlights crucial areas for design refinement, ultimately aiming to enhance adherence and overall outcomes.

  • Open Access

    Understanding the relationship between adolescents with tuberculosis and health services: an indepth qualitative study from Cape Town

    by Dillon Timothy Wademan, Graeme Hoddinott, Zara Kavalieratos, Mfundo Mlomzale, Arlene J Marthinus, Lucia N Jola, Stephanie Jacobs, Khanyisa Mcimeli, James Seddon

    Introduction Adolescents’ experiences (10–19 years-old) with tuberculosis (TB) remain poorly understood. Descriptions of adolescent TB experiences, particularly how they interact with the health system, are scarce. We aimed to understand adolescents’ experiences of TB health services in the Western Cape, South Africa. We focused on how TB services were aided or hindered through interactions with healthcare providers and health system processes. Methods Teen TB, an observational study in Cape Town, enrolled 50 newly diagnosed adolescents with multidrug-resistant and drug-susceptible TB. A subset of 20 was selected for serial qualitative data collection, with 19 completing all tasks between December 2020 and September 2021. 52 interviews were conducted and thematically analysed using a case descriptive process for experiences across the TB care cascade. Findings Adolescents criticised the difficulties and delays they encountered in obtaining an accurate TB diagnosis. Initial misdiagnoses and delayed TB diagnoses were reported, despite seeking help from multiple healthcare providers at different facilities. Adolescents questioned whether the financial, social and emotional costs of TB care outweighed the costs of delaying treatment initiation and adherence. Adolescents reported that the treatment regimen, adherence support processes and interactions with the health system posed significant challenges to maintaining adherence. Encouragingly, however, most adolescents reported being well treated and cared for by health workers. Conclusion Our study shows that adolescents experience challenges throughout their TB treatment journeys. More adolescent-focused research is needed to tailor treatment and healthcare processes to their needs.


  • Open Access

    A historical narrative review of the emerging priority of acceptability in tuberculosis treatment in children

    by Dillon T. Wademan, H. Simon Schaaf, Peter R. Donald, Anneke C. Hesseling, René Raad, Graeme Hoddinott, Ria Reis, Lindsey Reynolds

  • Open Access

    Psychosocial experiences of adolescents with tuberculosis in Cape Town

    by Dillon T. Wademan, Mfundo Mlomzale, Arlene J. Marthinus, Stephanie Jacobs, Khanyisa Mcimeli, Klassina Zimri, James A. Seddon, Graeme Hoddinott

    Adolescents (10-19-years-old) account for almost 10% of the annual global tuberculosis (TB) incidence. Adolescents’ experiences of TB care, TB stigma, and the consequences of TB for their relationships, schooling, and mental health are different, and often more severe, compared to younger children and adults. How TB impacts the lives of adolescents is not well described or understood. We aimed to locate adolescents’ experiences of TB relative to their psychosocial contexts, describe the impact of TB on adolescents’ wellbeing, and describe how TB and its treatment affects their socio-familial contexts. Teen TB was a prospective observational cohort study which recruited 50 adolescents with newly diagnosed TB disease (including both multidrug-resistant TB and drug-susceptible TB) in Cape Town, South Africa. A nested sub-sample of 20 adolescents were purposively sampled for longitudinal qualitative data collection. Nineteen participants completed all qualitative data collection activities between December 2020 and September 2021. Adolescents described their communities as undesirable places to live—rife with violence, poverty, and unemployment. The negative experiences of living in these conditions were exacerbated by TB episodes among adolescents or within their households. TB and its treatment disrupted adolescents’ socio-familial connections; many participants described losing friendships and attachment to family members as people reacted negatively to their TB diagnosis. TB, inclusive of the experience of disease, diagnosis and treatment also negatively impacted adolescents’ mental health. Participants reported feeling depressed, despondent, and at times suicidal. TB also disrupted adolescents’ schooling and employment opportunities as adolescents were absent from school and college for substantial periods of time. Our findings confirm that adolescents’ psychosocial experiences of TB are often highly negative, compounding underlying vulnerability. Future research should prioritize exploring the potential of social protection programmes providing adolescents and their families with psychosocial and economic support.


  • Open Access

    Holistic acceptability of an adult levofloxacin formulation in children and adolescents on a tuberculosis preventive treatment trial

    by Susan E. Purchase, Dillon T. Wademan, Nosibusiso L. Tshetu, Mohhadiah Rafique, Graeme Hoddinott, James A. Seddon, H. Simon Schaaf, Anneke C. Hesseling

    Drug-resistant tuberculosis (TB) is threatening global TB control. Although formulations designed for children are a priority, adult levofloxacin formulations are widely used in TB treatment and prevention. TB-CHAMP was a cluster-randomised, placebo-controlled trial evaluating the efficacy and safety of 24 weeks of daily levofloxacin to prevent TB in child and adolescent household contacts of adults with infectious multidrug-resistant TB. Nested in-depth longitudinal qualitative work was conducted in a subset of children and their caregivers to understand broader experiences of treatment acceptability. We conducted 41 interviews with 8 caregivers of children <6 years, and with 6 older children responding for themselves. Children who could not swallow the adult formulation whole, found the tablet unpalatable, although they learnt to tolerate the taste over time. Most caregivers and children came from families with substantial experience of TB, but felt they knew little about TB preventive therapy. Many families experienced challenging socio-economic circumstances. Poor acceptability was mitigated by sympathetic study personnel, assistance with transport and financial compensation. The adult formulation of levofloxacin was disliked by many younger children but was acceptable to children able to swallow the tablet whole. In addition to using acceptable drug formulations, TB preventive treatment implementation models should include patient education and should accommodate patients’ socioeconomic challenges.


  • Including the Voice of Children < 15-Years-Old in Paediatric Global Health Research

    by Dillon T. Wademan, Jean Hunleth, Musonda Simwinga, Tahiya Mahbub, Sarah Bernays, Graeme Hoddinott, Amrita Daftary

    Purpose of Review Despite evidence of the benefits of including children’s voices in global health research, they continue to be underrepresented. Implementation of how to include children’s voices appears to remain an obstacle to their inclusion in global health research. In this manuscript, we present an epistemological frame that advocates children as experts of their own experiences and knowledge-bearers. Then we provide four case studies, to illustrate ongoing efforts to build equity in the design and execution of paediatric health research. Recent Findings Ensuring children’s equitable inclusion requires recognizing them as active participants in their health and wellbeing, and empowering them to employ their agency in all interactions with researchers, while recognizing the dialogical nature of those interactions. Successfully involving children in global health research can lead to important psychosocial and clinical insights, that could be leveraged to inform future treatment and care practices. Summary We present four case studies describing the inclusion of children in research and research development related to prevention, treatment and/or care of chronic and acute diseases (tuberculosis, HIV, cervical and other forms of cancer) in a number of global settings including India, Philippines, South Africa, United States, Zambia. The exemplars detail novel applications of a diversity of arts-based methods that are rooted in frameworks for participatory action research. They highlight the need to invest funds, training, time and resources for early and sustained engagement with children throughout the research process. We conclude by offering principles for equitably engaging children in global health research.


  • Acceptability of clofazimine capsules in children and adolescents with rifampicin-resistant TB

    by D.T. Wademan, Z. Saule, A. Marthinus, L. Viljoen, E. Nortier, J. Hughes, I. Courtney, M. Palmer, A.J. Garcia-Prats, A.C. Hesseling, et al.


  • Open Access

    Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment

    by D. T. Wademan, H. R. Draper, S. E. Purchase, M. Palmer, A. C. Hesseling, L. Van der Laan, A. J. Garcia-Prats

    SUMMARY: BACKGROUND: We evaluated the palatability and acceptability of a 100 mg dispersible and a non-dispersible 250 mg levofloxacin (LVX) tablet formulation in children. METHODS: Perform was a randomised, open-label, cross-over trial of the relative bioavailability of LVX dispersible vs. crushed non-dispersible tablets in children aged n = 14, 56%), vomiting/spitting out medicines ( n = 11, 44%), and children refusing medicines ( n = 10, 40%). Caregivers reported that the dispersible formulation was easier for their child to take than the non-dispersible formulation ( P = 0.0253). Mean ranks for caregiver’s formulation preferences (dispersible tablets: 1.48, SD ±0.71; non-dispersible tablets: 2.12, SD ±0.67; routinely available formulations: 2.40 SD ±0.82) differed significantly (Friedman’s F 11.120; P < 0.0038); post-hoc testing showed dispersible tablets were preferred over non-dispersible ( P = 0.018) and routinely available LVX formulations ( P < 0.001). CONCLUSIONS: The dispersible LVX 100 mg tablet formulation was preferred and should be prioritised for integration into routine care.